Why PepCue exists.
PepCue is a free tracking app for peptides and GLP-1 medications, and an evidence-first reference for the compounds people are actually taking. It runs on one rule: say what the research shows, including when the honest answer is that nobody has looked yet.
The problem
Peptides are one of the few subjects where the confidence of the writing is inversely related to the strength of the evidence behind it. A compound with a dozen rodent studies and no human trial gets described in the same register as an approved drug with a large outcomes trial behind it. The mechanism story is told well, the absence of human data goes unmentioned, and a reader without access to the literature has no way to tell the two apart.
That gap is the reason this site exists. Every compound here is graded on the strength of its published human evidence, and the model that produces the grade is written out in full rather than hinted at.
What we build
Two things. The app is a free tracker for iPhone and Android: dose logging, schedules and reminders, injection site rotation, reconstitution and vial math, inventory and expiry, cost per dose, and progress charts. Tracking data stays on the device, and you can start without an account.
The site is the reference half: 69 compound profiles graded S to F, roughly 306 citations checked against the live NCBI record, free calculators with no sign-up, plus guides, mechanism explainers, comparisons, a glossary and a blog. The two halves are joined on purpose. The practical question and the evidence question arrive at the same moment, and splitting them across two products has never helped anybody.
How it is funded
The app is free. We take no affiliate commissions, no vendor sponsorship, and no payment for coverage or placement. We do not sell peptides, rank suppliers, or carry ads for them. There is nothing on this site you can buy.
That matters more than it sounds. Almost every well-written peptide resource online is attached to something being sold, and the incentive that creates is not subtle: the compounds that sell well get the generous write-ups. Removing the revenue removes the incentive. If PepCue ever charges for anything it will be for the app, and the grades will still be governed by the scoring model alone.
The editorial stance
Human evidence outranks mechanism. A plausible pathway is a reason to run a trial, not a result, so preclinical-only compounds are labelled preclinical-only however good the story sounds.
Unverified is not the same as false. Most claims about research peptides have never been properly tested, and calling that disproven would be as dishonest as calling it proven. The tier board keeps those verdicts separate.
Popularity can only ever lower a grade, never raise one: when a compound is widely discussed and thinly evidenced, the distance between the two is itself a finding. And every claim resolves to a real paper, regulatory document, or registry entry, with every identifier machine-checked against the live NCBI record. Anything that fails to resolve does not ship.
Who it is for
People already taking something, or about to, who want to know what is genuinely established. Clinicians who would rather have a citation list than a forum thread. And people still deciding whether to start at all, who are entitled to read the unflattering version first.
It is not written for people looking for permission. If you arrive hoping a page will tell you a compound is fine, the profiles will frustrate you, and that is the intended behaviour.
What we refuse to do
We do not publish doses, protocols, cycles, or titration schedules for research compounds. Where a number appears in a calculator it is arithmetic on figures you entered, and where a schedule appears it is a reproduction of an approved manufacturer label, attributed as such.
We do not name or rank vendors we have not verified, we do not treat a certificate of analysis as a safety guarantee, and we do not invent a citation to fill a gap. Where nothing has been published, the profile says nothing has been published.
Corrections
Grades are not permanent. They move when the evidence moves: a published trial, a new approval, a failed endpoint, a withdrawal. Content carries a reviewed date, and every page has a link to flag an error. If you can point to a source we got wrong, write to kam@pepcue.app. Being corrected is cheaper than being wrong quietly.
Start with the compound index, sort by the evidence board, or read how the grading works. Support questions live in the help centre and the FAQ.